Tata Elxsi Selected As Certified 3PL Partner for Google Widevine

October 15, 2020

Tata Elxsi, a world-leading design and technology services company, is pleased to announce its selection as a 3PL certification partner for Google Widevine, to deliver secure premium content protection for Broadcast, Media, Consumer Electronics, and Automotive applications.

Tata Elxsi notes this certification partnership further expands Tata Elxsi’s offerings and leadership in the broadcast, media, consumer devices, and automotive domains, and enables leading brands, content distributors, OTT providers and operators with a seamless development, integration, and certification service for Widevine solutions ensuring faster time-to-market for their revenue-generating services.

Google Widevine enables secure premium content protection on any consumer device, utilizing free-to-use, standards-based solutions for OTT, and CAS services. It has been used in over 5 Billion devices today and is trusted by PayTV providers and broadcasters who deliver premium content over an OTT network such as Netflix, HBO, Disney, Amazon Prime, Jio, Warner Bros and more. Through this program, Google plans to scale the adoption of the Widevine CAS solutions by enabling select chosen partners for certification activities.

“In line with the trust our customers and partners have in us, we are delighted to select Tata Elxsi as a Certified 3PL Partner. Tata Elxsi’s strong ecosystem in the Broadcast, OTT, Consumer devices, and Mobility markets, understanding of cloud-native applications, and world class user experience capabilities will help accelerate the adoption of our Widevine solutions by customers. The collaboration between the two teams has been outstanding and will continue to ensure a wonderful customer experience.” said Brian Baker, Senior Director and head of Widevine at Google.

This is the first time the 3PL partnership model has been instituted, and we are delighted to have been selected for this program and extend our partnership with Google and Widevine. This will accelerate the adoption of Widevine solutions by customers and their time to market for new products and revenue-generating services, “said Nitin Pai, Chief Marketing and Strategy Officer, Tata Elxsi.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.